Supplementary Fig. 14: Generation of the anti-murine EGFR D1D4J APEC which has no effect on survival compared to control IgG as single agent therapy. | Nature Biotechnology

Supplementary Fig. 14: Generation of the anti-murine EGFR D1D4J APEC which has no effect on survival compared to control IgG as single agent therapy.

From: Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy

Supplementary Fig. 14

(a) Flow cytometry analysis of the murine colorectal cell line SL-4 demonstrates cells positive for both EGF receptor (D1D4J antibody) and the MHC class I molecule H2-kb (MHC I allele which presents the SIINFEKL peptide) (data from single experiment). (b) T cell function assay demonstrating the production and detection of lacZ by the activated B3Z T cell hybridoma after recognizing SL-4 cells exogenously labelled with SIINFEKL peptide (n=3 independent samples). Data represented as mean and error bars represent standard error of the mean. (c) SL-4 cell line labelled with a library of 35 D1D4J-APECs and lacZ production by B3Z T cells assayed. (d) Immunocompetent mice used in the SL4 colorectal cancer model treated with single agent D1D4J-APEC therapy demonstrated no difference in survival compared with mice treated with control IgG (n=10). Significance was determined by Mantel Cox test (two-sided).

Back to article page